Newron Pharmaceuticals S.p.A. (SIX: NWRN, XETRA: NP5) announced that its shareholders approved all motions on the agenda for the ordinary part of the Annual General Meeting (AGM) 2026 held today. The approvals included the election of George Garibaldi and Paolo Zocchi as new, independent, and non-executive Board members. The motions for the extraordinary part of the meeting were not put to vote because the required quorum was not reached.
Chris Martin, Chairman of the Board of Directors of Newron, expressed gratitude to shareholders for their trust and welcomed the newly elected Board members. He also thanked Patrick Langlois and Luca Benatti, who stepped down after long-standing service, for their support of the company.
Newron Pharmaceuticals is a biopharmaceutical company focused on developing novel therapies for patients with central and peripheral nervous system diseases. The company's lead compound, evenamide, is a first-in-class glutamate modulator being developed as an add-on therapy for treatment-resistant schizophrenia (TRS) and poorly responding patients with schizophrenia. Evenamide is currently in the global pivotal ENIGMA-TRS Phase III development program. Clinical trial results have shown significant improvements across key efficacy measures increasing over time, along with a favorable safety profile.
Newron has signed development and commercialization agreements for evenamide with EA Pharma (a subsidiary of Eisai) for Japan and other Asian territories, as well as Myung In Pharm for South Korea. The company's first marketed product, Xadago®/safinamide, has received marketing authorization for the treatment of Parkinson's disease in multiple regions, including the European Union, Switzerland, the UK, the USA, Australia, Canada, Latin America, Israel, the United Arab Emirates, Japan, and South Korea. The product is commercialized by Newron's partner Zambon, with Supernus Pharmaceuticals holding marketing rights in the U.S., and Meiji Seika responsible for development and commercialization in Japan and other key Asian territories.
For more information, visit the company's website at www.newron.com. The original press release is available at www.newmediawire.com.
